BRAF and neoplasm: Subtype C expressed the BRAF mutant signature we identified earlier 6 (87.0%), a CIMP-H signature (11, Figure 2), and its characteristics (enrichment for MSI, right side and mucinous histology) corresponded with those of the previously reported CIMP-H phenotype 9—40 and hypermutated tumours 13.